Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of ...

The executive order aims to cut US prescription drug costs by linking them to the lowest prices paid internationally.

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...